Novo Nordisk (NVO) EPS (2014 - 2026)
Novo Nordisk (NVO) EPS from Dec 31, 2014 to Mar 31, 2026. The TTM Novo Nordisk (NVO) EPS is $4.29. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EPS
Quarterly EPS
Novo Nordisk (NVO) EPS CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +26.60% |
| 3 Years TTM | +31.10% |
| 5 Years TTM | +24.26% |
| 10 Years TTM | +15.65% |
| All Time TTM | +15.37% |
Annual EPS change of Novo Nordisk (NVO)
| Year | EPS | Change |
|---|---|---|
| 2026 | $1.69 | -53.39% |
| 2025 | $3.62 | +15.25% |
| 2024 | $3.14 | +13.97% |
| 2023 | $2.76 | +56.79% |
| 2022 | $1.76 | +10.89% |
| 2021 | $1.59 | +7.26% |
| 2020 | $1.48 | +20.27% |
| 2019 | $1.23 | +0.50% |
| 2018 | $1.22 | -1.33% |
| 2017 | $1.24 | +17.09% |
| 2016 | $1.06 | +7.62% |
| 2015 | $0.98 | +20.18% |
| 2014 | $0.82 | N/A |
Comparison Novo Nordisk (NVO) five years EPS CAGR with competitors
Novo Nordisk (NVO) five years EPS CAGR is 24.26%.
| Ticker | Name | five years EPS CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.59% | +306.45% |
| LLY | Lilly(Eli) & Company | 29.14% | +20.14% |
| AZN | Astrazeneca plc | 17.09% | -29.53% |
| JNJ | Johnson & Johnson | 11.59% | -52.22% |
| MRK | Merck & Co Inc | 5.37% | -77.85% |
| BMY | Bristol-Myers Squibb Company | 5.08% | -79.05% |
| GSK | GSK Plc | 4.65% | -80.82% |
| AMGN | AMGEN Inc | 3.49% | -85.59% |